关于 Siaα-2,6Gal 在肺癌早期诊断和鉴别诊断中应用潜力的多中心研究。

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-11-14 DOI:10.1016/j.cca.2024.120031

Si Yue , Yuhan Chen , Wenhao Cui , Xiuwei Lu , Yuhuan Shen , Feifei Zhou , Jinju Guan , Jierong Chen , Qiuyuan Wen , Yongjian Chen

{"title":"关于 Siaα-2,6Gal 在肺癌早期诊断和鉴别诊断中应用潜力的多中心研究。","authors":"Si Yue , Yuhan Chen , Wenhao Cui , Xiuwei Lu , Yuhuan Shen , Feifei Zhou , Jinju Guan , Jierong Chen , Qiuyuan Wen , Yongjian Chen","doi":"10.1016/j.cca.2024.120031","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to investigate the application potential of the abnormal glycan structure Siaα-2,6Gal in the early and differential diagnosis of lung cancer.</div></div><div><h3>Methods</h3><div>Clinical data and serum samples from 730 patients and 120 healthy individuals participating in clinical trials on Siaα-2,6Gal were collected at three medical centers between January 2022 and June 2023. The levels of Siaα-2,6Gal, carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen (CYFRA21-1), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (ProGRP) in serum were measured. The application potentials of these markers in the early and differential diagnosis, classification, and staging of lung cancer were explored.</div></div><div><h3>Results</h3><div>(1) Serum Siaα-2,6Gal levels in the lung cancer group were 2,606 (1,970–3,458) U/mL, significantly higher than those in the benign lung disease, miscellaneous malignant tumor, miscellaneous benign disease, and healthy individual groups at 1,359 (950–1,528), 1,252 (903–1,532), 1,196 (850–1,490), and 1,210 (1,100–1,287) U/mL (P < 0.0001). (2) Serum Siaα-2,6Gal levels in the early-stage lung cancer (stages 0–II) group were 2,576 (1,929–3,338) U/mL, significantly higher than those in the benign pulmonary nodule group at 1,419 (1,105–1,820) U/mL (P < 0.0001). (3) Receiver operating characteristic curves showed that Siaα-2,6Gal had a high diagnostic efficiency for lung cancer (area under the curve (AUC) = 0.9217), significantly superior to CEA, CYFRA21-1, SCC, NSE, and ProGRP (AUCs of 0.6618, 0.6605, 0.5783, 0.5985, and 0.6381).</div></div><div><h3>Conclusion</h3><div>Siaα-2,6Gal is a promising biomarker for lung cancer diagnosis and may offer superior differential diagnosis of early-stage lung cancer from benign pulmonary nodules compared to traditional tumor markers.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"566 ","pages":"Article 120031"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer\",\"authors\":\"Si Yue , Yuhan Chen , Wenhao Cui , Xiuwei Lu , Yuhuan Shen , Feifei Zhou , Jinju Guan , Jierong Chen , Qiuyuan Wen , Yongjian Chen\",\"doi\":\"10.1016/j.cca.2024.120031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>This study aimed to investigate the application potential of the abnormal glycan structure Siaα-2,6Gal in the early and differential diagnosis of lung cancer.</div></div><div><h3>Methods</h3><div>Clinical data and serum samples from 730 patients and 120 healthy individuals participating in clinical trials on Siaα-2,6Gal were collected at three medical centers between January 2022 and June 2023. The levels of Siaα-2,6Gal, carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen (CYFRA21-1), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (ProGRP) in serum were measured. The application potentials of these markers in the early and differential diagnosis, classification, and staging of lung cancer were explored.</div></div><div><h3>Results</h3><div>(1) Serum Siaα-2,6Gal levels in the lung cancer group were 2,606 (1,970–3,458) U/mL, significantly higher than those in the benign lung disease, miscellaneous malignant tumor, miscellaneous benign disease, and healthy individual groups at 1,359 (950–1,528), 1,252 (903–1,532), 1,196 (850–1,490), and 1,210 (1,100–1,287) U/mL (P < 0.0001). (2) Serum Siaα-2,6Gal levels in the early-stage lung cancer (stages 0–II) group were 2,576 (1,929–3,338) U/mL, significantly higher than those in the benign pulmonary nodule group at 1,419 (1,105–1,820) U/mL (P < 0.0001). (3) Receiver operating characteristic curves showed that Siaα-2,6Gal had a high diagnostic efficiency for lung cancer (area under the curve (AUC) = 0.9217), significantly superior to CEA, CYFRA21-1, SCC, NSE, and ProGRP (AUCs of 0.6618, 0.6605, 0.5783, 0.5985, and 0.6381).</div></div><div><h3>Conclusion</h3><div>Siaα-2,6Gal is a promising biomarker for lung cancer diagnosis and may offer superior differential diagnosis of early-stage lung cancer from benign pulmonary nodules compared to traditional tumor markers.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"566 \",\"pages\":\"Article 120031\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898124022848\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898124022848","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

研究目的本研究旨在探讨异常聚糖结构 Siaα-2,6Gal 在肺癌早期诊断和鉴别诊断中的应用潜力：方法：2022 年 1 月至 2023 年 6 月期间，在三个医疗中心收集了参与 Siaα-2,6Gal 临床试验的 730 名患者和 120 名健康人的临床数据和血清样本。测量了血清中 Siaα-2,6Gal、癌胚抗原（CEA）、细胞角蛋白 19 片段抗原（CYFRA21-1）、鳞状细胞癌抗原（SCC）、神经元特异性烯醇化酶（NSE）和促胃泌素释放肽（ProGRP）的水平。探讨了这些标记物在肺癌早期诊断、鉴别诊断、分类和分期中的应用潜力。结果：（1）肺癌组血清 Siaα-2,6Gal 水平为 2,606 (1,970-3,458) U/mL，明显高于肺良性疾病组、恶性肿瘤杂项组、良性疾病杂项组和健康人组的 1,359 (950-1,528)、1,252 (903-1,532)、1,196 (850-1,490) 和 1,210 (1,100-1,287) U/mL（P < 0.0001).(2）早期肺癌（0-II期）组血清Siaα-2,6Gal水平为2,576（1,929-3,338） U/mL，显著高于良性肺结节组的1,419（1,105-1,820） U/mL（P < 0.0001）。(3）接收者操作特征曲线显示，Siaα-2,6Gal对肺癌的诊断率较高（曲线下面积（AUC）= 0.9217），明显优于CEA、CYFRA21-1、SCC、NSE和ProGRP（AUC分别为0.6618、0.6605、0.5783、0.5985和0.6381）：结论：Siaα-2,6Gal 是一种很有前景的肺癌诊断生物标记物，与传统的肿瘤标记物相比，它能更好地鉴别诊断早期肺癌和良性肺结节。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer

Objective

This study aimed to investigate the application potential of the abnormal glycan structure Siaα-2,6Gal in the early and differential diagnosis of lung cancer.

Methods

Clinical data and serum samples from 730 patients and 120 healthy individuals participating in clinical trials on Siaα-2,6Gal were collected at three medical centers between January 2022 and June 2023. The levels of Siaα-2,6Gal, carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen (CYFRA21-1), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (ProGRP) in serum were measured. The application potentials of these markers in the early and differential diagnosis, classification, and staging of lung cancer were explored.

Results

(1) Serum Siaα-2,6Gal levels in the lung cancer group were 2,606 (1,970–3,458) U/mL, significantly higher than those in the benign lung disease, miscellaneous malignant tumor, miscellaneous benign disease, and healthy individual groups at 1,359 (950–1,528), 1,252 (903–1,532), 1,196 (850–1,490), and 1,210 (1,100–1,287) U/mL (P < 0.0001). (2) Serum Siaα-2,6Gal levels in the early-stage lung cancer (stages 0–II) group were 2,576 (1,929–3,338) U/mL, significantly higher than those in the benign pulmonary nodule group at 1,419 (1,105–1,820) U/mL (P < 0.0001). (3) Receiver operating characteristic curves showed that Siaα-2,6Gal had a high diagnostic efficiency for lung cancer (area under the curve (AUC) = 0.9217), significantly superior to CEA, CYFRA21-1, SCC, NSE, and ProGRP (AUCs of 0.6618, 0.6605, 0.5783, 0.5985, and 0.6381).

Conclusion

Siaα-2,6Gal is a promising biomarker for lung cancer diagnosis and may offer superior differential diagnosis of early-stage lung cancer from benign pulmonary nodules compared to traditional tumor markers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.